. Overview We are a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using our patented iSPERSE technology. Our proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis ...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001493152-26-008130 | EDGAR | 73K words |
| 2025-03-21 | 2024-12-31 | 0001493152-25-011084 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001493152-24-011630 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009609 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001493152-22-007957 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001493152-21-006602 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001193125-20-086168 | EDGAR | — |
| 2019-02-19 | 2018-12-31 | 0001193125-19-043624 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001193125-18-080793 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001193125-17-077912 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-16 | 2025-09-30 | 0001493152-25-018256 | EDGAR | 16K words |
| 2025-08-06 | 2025-06-30 | 0001641172-25-022357 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010533 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001493152-24-044163 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031478 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001493152-24-018579 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040012 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001493152-23-027468 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016514 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031256 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001493152-22-021838 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001493152-22-012940 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001493152-26-013266 | EDGAR | 57K words |
| 2026-03-02 | 0001493152-26-008449 | EDGAR | — |
| 2026-02-26 | 0001493152-26-008129 | EDGAR | — |
| 2025-12-18 | 0001493152-25-028283 | EDGAR | — |
| 2025-10-16 | 0001493152-25-018252 | EDGAR | — |
| 2025-08-06 | 0001641172-25-022354 | EDGAR | — |
| 2025-06-16 | 0001641172-25-015249 | EDGAR | — |
| 2025-05-15 | 0001641172-25-010525 | EDGAR | — |
| 2025-04-10 | 0001641172-25-003620 | EDGAR | — |
| 2025-04-08 | 0001641172-25-003216 | EDGAR | — |
292 total filings indexed. 260 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001574235 |
| Ticker | PULM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pulmatrix.com |
| Listed | 2014-03-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report